Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has provided specialised treatment to a child from Egypt diagnosed with Duchenne Muscular Dystrophy (DMD).
Division Chief of Genetics and Genomic Medicine at Sidra Medicine, Professor Tawfeg Ben-Omran said, “Since announcing the extension of the Duchenne Muscular Dystrophy gene therapy programme for older children, we have treated 10 patients to date and continue to attract patients from around the region.”
Aly, a 10-year-old boy, arrived from Egypt with his parents in December 2025 for DMD treatment.
Following several weeks of clinical evaluation and eligibility assessment, Aly was administered the gene therapy infusion on March 1 2026 under the supervision of the hospital’s specialised Gene Therapy Team.
Aly’s parents said, “Following a long and difficult journey to reach an accurate diagnosis, Aly was diagnosed with Duchenne Muscular Dystrophy at the age of three. The journey deeply impacted our family until we were able to bring him to Qatar for treatment.
“We are grateful to Sidra Medicine and the State of Qatar for the exceptional care and support provided to our son. It has given us renewed hope and confidence as we continue his treatment journey and celebrate his health milestones.”
Chief Medical Officer at Sidra Medicine, Prof. Ibrahim Janahi said, “Sidra Medicine remains committed to ensuring continuity of care for children with complex and rare conditions.”
After receiving the therapy, Aly entered a structured post-infusion monitoring protocol designed to ensure safety and support his recovery. Aly will also undergo regular physiotherapy evaluations to monitor mobility and functional progress before being discharged and ready to fly back home to Egypt. Aly’s treatment programme highlights the positive clinical outcomes of gene therapy for Duchenne Muscular Dystrophy patients at Sidra Medicine.
